Continuing challenges of sepsis research

JAMA. 2001 Oct 17;286(15):1894-6. doi: 10.1001/jama.286.15.1894.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use*
  • Antithrombin III / therapeutic use*
  • Clinical Trials as Topic
  • Drug Interactions
  • Heparin / therapeutic use
  • Humans
  • Multiple Organ Failure / etiology*
  • Multiple Organ Failure / prevention & control
  • Protein C / therapeutic use*
  • Recombinant Proteins / therapeutic use*
  • Serine Proteinase Inhibitors / therapeutic use*
  • Shock, Septic / complications
  • Shock, Septic / drug therapy*
  • Shock, Septic / physiopathology*
  • Systemic Inflammatory Response Syndrome / complications
  • Systemic Inflammatory Response Syndrome / drug therapy
  • Systemic Inflammatory Response Syndrome / physiopathology

Substances

  • Anticoagulants
  • Protein C
  • Recombinant Proteins
  • Serine Proteinase Inhibitors
  • Antithrombin III
  • Heparin
  • drotrecogin alfa activated